Oded Kraft is the CEO and co-founder of GrayMatters Health, a company developing non-drug, non-invasive interventional psychiatry treatments powered by behavioral brain-computer interface (BCI) technology and digital brain biomarkers, focusing on regions such as the amygdala and ventral striatum. The company’s first product, designed for the treatment of PTSD, has been cleared by the FDA. The data collected during treatments is then used to advance precision, objective psychiatry.
With over 25 years of experience in both corporate and startup environments across Israel, the US, and Germany, Kraft has held leadership positions in prominent organizations. He served as a Global P&L Leader at GE Healthcare’s Nuclear Medicine division, overseeing GE’s NM and PET-CT applications. He also held an executive business role and was a scout with Roche Diabetes Care division in Germany, where he led the division’s 10-year, $3B product portfolio and strategic roadmap. Additionally, Kraft served as VP of Products and Business Development at Medingo, a medical device company acquired by Roche GmbH, and as VP of Product Development at Kornit Digital.
Kraft worked for five years with a Department of Defense company in the USA. He holds an MBA and a BSc in Electrical Engineering from the Technion–Israel Institute of Technology.